Elizabeth M Garry

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Venues

Pharmacoepidemiology and drug safety

Vaccines

Diabetes, obesity & metabolism

Clinical pharmacology and therapeutics

Aetion (United States)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Aetion (United States)

United States

Principal Scientist :: Science

Publications

Soowoo Back, Bethany Knox, Ciara Coakley, Nicolas Deltour, Emmanuelle Jacquot, Hanaya Raad, Elizabeth M Garry
Effectiveness and Safety of the MVA-BN Vaccine against Mpox in At-Risk Individuals in the United States (USMVAc). Vaccines 12 (6) (2024)
Jessica C Young, Michael A Webster-Clark, Shahar Shmuel, Elizabeth M Garry, Panagiotis Mavros, Til Stürmer, Cynthia J Girman
Clarifying the causal contrast: An empirical example applying the prevalent new user study design. Pharmacoepidemiology and drug safety 33 (4) (2024)
Soowoo Back, Bethany Knox, Ciara Coakley, Nicolas Deltour, Emmanuelle Jacquot, Hanaya Raad, Elizabeth M Garry
Effectiveness and Safety of the MVA-BN Vaccine against Mpox in At-Risk Individuals in the United States (USMVAc). Vaccines 12 (6) (2024)
Soowoo Back, Bethany Knox, Ciara Coakley, Nicolas Deltour, Emmanuelle Jacquot, Hanaya Raad, Elizabeth M Garry
Effectiveness and Safety of the MVA-BN Vaccine against Mpox in At-Risk Individuals in the United States (USMVAc). Vaccines 12 (6) (2024)
Liza R Gibbs, Ayad K Ali, Dawn G Albright, Emily R Rubinstein, Reyna J Klesh, Ruth Zimmerman, Elizabeth M Garry
Characteristics and outcomes of pregnancies in the Maternal Outcomes Masterset real-world database. Pharmacoepidemiology and drug safety (2023)
Elizabeth M Garry, Andrew R Weckstein, Kenneth Quinto, Marie C Bradley, Tamar Lasky, Aloka G Chakravarty, Sandy Leonard, Sarah E Vititoe, Imaani J Easthausen, Jeremy A Rassen, Nicolle M Gatto
Categorization of COVID-19 severity to determine mortality risk. Pharmacoepidemiology and drug safety 31 (7) (2022)
Michael A Webster-Clark, Panagiotis Mavros, Elizabeth M Garry, Til Stürmer, Shahar Shmuel, Jessica C Young, Cynthia J Girman
Alternative analytic and matching approaches for the prevalent new-user design: A simulation study. Pharmacoepidemiology and drug safety 31 (7) (2022)
Sarah E Vititoe, Imaani J Easthausen, Tamar Lasky, Aloka G Chakravarty, Marie C Bradley, Laura M Roe, Nicolle M Gatto, Andrew R Weckstein, Elizabeth M Garry
Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemic. PloS one 17 (9) (2022)
Christina A Purpura, Elizabeth M Garry, Nicholaas Honig, Abigail Case, Jeremy A Rassen
The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. Clinical pharmacology and therapeutics (2021)
Elizabeth M Garry, John B Buse, Mugdha N Gokhale, Jennifer L Lund, Matthew E Nielsen, Virginia Pate, Til Stürmer
Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. Diabetes, obesity & metabolism 21 (9) (2019)
Elizabeth M Garry, John B Buse, Jennifer L Lund, Virginia Pate, Til Stürmer
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. Diabetes, obesity & metabolism 20 (1) (2017)

Elizabeth M Garry.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Elizabeth M Garry